Table 1 Neurotransmitter receptors and transporters included in analyses. BP_ND, non-displaceable binding potential; V_T, tracer distribution volume; B_max, density (pmol ml⁻¹) converted from binding potential (5-HT) or distributional volume (GABA) using autoradiography-derived densities; SUVR, standard uptake value ratio. Values in parentheses (under n) indicate the number of females. Neurotransmitter receptor maps without citations refer to previously unpublished data. In those cases, contact information for the study principal investigator (PI) is provided in Supplementary Table 3. Supplementary Table 3 also includes more extensive methodological details, such as PET camera, number of males and females, modeling method, reference region, scan length and modeling notes. Asterisks indicate transporters

D₁

Dopamine

[¹¹C]SCH23390

BP_ND

13 (7)

33 ± 13

Kaller et al.⁵⁸

D₂

Dopamine

[¹¹C]FLB-457

BP_ND

37 (20)

48.4 ± 16.9

Smith et al.^59,60

D₂

Dopamine

[¹¹C]FLB-457

BP_ND

55 (29)

32.5 ± 9.7

Sandiego et al.^{59,60,61,62,63}

DAT^*

Dopamine

[¹²³I]-FP-CIT

SUVR

174 (65)

61 ± 11

Dukart et al.⁶⁴

NET^*

Norepinephrine

[¹¹C]MRB

BP_ND

77 (27)

33.4 ± 9.2

Ding et al.^65,66,67,68

5-HT_1A

Serotonin

[¹¹C]WAY-100635

BP_ND

35 (17)

26.3 ± 5.2

Savli et al.⁶⁹

5-HT_1B

Serotonin

[¹¹C]P943

BP_ND

65 (16)

33.7 ± 9.7

Gallezot et al.^{70,71,72,73,74,75,76}

5-HT_1B

Serotonin

[¹¹C]P943

BP_ND

23 (8)

28.7 ± 7.0

Savli et al.⁶⁹

5-HT_2A

Serotonin

[¹¹C]Cimbi-36

B\({}_{\max}\)

29 (14)

22.6 ± 2.7

Beliveau et al.⁹

5-HT₄

Serotonin

[¹¹C]SB207145

B\({}_{\max}\)

59 (18)

25.9 ± 5.3

Beliveau et al.⁹

5-HT₆

Serotonin

[¹¹C]GSK215083

BP_ND

30 (0)

36.6 ± 9.0

Radhakrishnan et al.^77,78

5-HTT^*

Serotonin

[¹¹C]DASB

B\({}_{\max}\)

100 (71)

25.1 ± 5.8

Beliveau et al.⁹

α₄β₂

Acetylcholine

[¹⁸F]Flubatine

V_T

30 (10)

33.5 ± 10.7

Hillmer et al.^79,80

M₁

Acetylcholine

[¹¹C]LSN3172176

BP_ND

24 (11)

40.5 ± 11.7

Naganawa et al.⁸¹

VAChT^*

Acetylcholine

[¹⁸F]FEOBV

SUVR

4 (1)

37 ± 10.2

PI: Tuominen, L. & Guimond, S.

VAChT^*

Acetylcholine

[¹⁸F]FEOBV

SUVR

18 (13)

66.8 ± 6.8

Aghourian et al.⁸²

VAChT^*

Acetylcholine

[¹⁸F]FEOBV

SUVR

5 (1)

68.3 ± 3.1

Bedard et al.⁸³

VAChT^*

Acetylcholine

[¹⁸F]FEOBV

SUVR

3 (3)

66.6 ± 0.94

PI: Schmitz, T. W. & Spreng, R. N.

NMDA

Glutamate

[¹⁸F]GE-179

V_T

29 (8)

40.9 ± 12.7

Galovic et al.^84,85,86

mGluR₅

Glutamate

[¹¹C]ABP688

BP_ND

73 (48)

19.9 ± 3.04

Smart et al.⁵²

mGluR₅

Glutamate

[¹¹C]ABP688

BP_ND

22 (10)

67.9 ± 9.6

PI: Rosa-Neto, P. & Kobayashi, E.

mGluR₅

Glutamate

[¹¹C]ABP688

BP_ND

28 (13)

33.1 ± 11.2

DuBois et al.⁸⁷

GABA_A/BZ

GABA

[¹¹C]Flumazenil

B\({}_{\max}\)

16 (9)

26.6 ± 8

Nørgaard et al.⁸

H₃

Histamine

[¹¹C]GSK189254

V_T

8 (1)

31.7 ± 9.0

Gallezot et al.⁸⁸

CB₁

Cannabinoid

[¹¹C]OMAR

V_T

77 (28)

30.0 ± 8.9

Normandin et al.^89,90,91,92

MOR

Opioid

[¹¹C]Carfentanil

BP_ND

204 (72)

32.3 ± 10.8

Kantonen et al.⁹³